In vitro Anti‐tumor Activity of Anti‐c‐erbB‐2 × Anti‐CD3ɛ Bifunctional Monoclonal Antibody

Publisher Website
Google Scholar
Abstract
With the aim of developing an effective cancer immunotherapy for common epithelial cancer, a new class of bifunctional antibody (BFA) was developed; one arm of this BFA recognized c‐erbB‐2 gene product, and the other arm recognized CD3ɛ, a T‐cell specific surface antigen. Application of this BFA with human peripheral blood lymphocytes exhibited specific anti‐tumor activity in vitro on a breast tumor cell line, ZR‐75–1, which expressed abundant c‐erbB‐2 gene product on its cell surface. These results indicate that BFA recognizing an oncogene product on cell surface is a potential new agent for cancer immunotherapy.